Schaeffer Center experts analyze the connection between medications for chronic diseases and their impact on Alzheimer’s as well as a lack of representation among racial and ethnic minorities in clinical trials.
Other featured articles
Future Health Dividends for California: Valuing Medical Innovations
Reducing the incidence of four common cancers (breast, colon, lung, and prostate cancer), diabetes and stroke by 50 percent would generate nearly $900 billion in social value for California between 2018 and 2040. Just a 10 percent decline generates $175 billion over the same period.
Are High-Deductible Plans a Healthy Option for Patients?
High-deductible health plans may have unintended consequences for patients.Posted in
State-Level Chart Books on the Cost of Mental Illness
As state policymakers assess new proposals to improve mental health treatment and access, understanding the population affected, the coverage gaps and the overall economic burden is integral to developing sustainable solutions that meet the need.Posted in
The Future of Cures: Investing in Value, Innovation and Access
High-cost drugs can generate even higher societal value when they combat serious disease, which should be accounted for in financing methods and pricing models to encourage medical innovation.Posted in
Our Work In Issue Briefs
Innovation in Heart Failure Treatment: Lengthening Lives and Narrowing Disparities
Despite recent gains in medical innovation and evidence-based treatment of heart failure and associated risk factors, the incidence of heart failure is expected to double among 65- to 75- year olds by 2030 according to a new analysis by Schaeffer Center researchers.
Reducing Infections While Cutting Costs: Eliminating Antibiotic Overprescriptions
Low-cost nudges that reduce unnecessary antibiotic prescriptions can improve health outcomes, save resources and help guard against the rise in drug-resistant bacteria.
Medicaid Access Restrictions on Psychiatric Drugs: Penny-Wise or Pound-Foolish?
Not only do formulary restrictions save little — if any — money on drug spending, they increase overall Medicaid spending for serious mental illnesses and may drive up incarceration costs.
Building the Private Healthcare Sector in the Developing World
In countries where the private sector plays a larger role in public health, people have more access with fewer disparities in care.
HIV/AIDS Treatment and U.S. Healthcare Policy: Landmark Gains or Missed Opportunities?
Coverage expansion under the Affordable Care Act (ACA) could remove barriers to HIV testing and care critical to treating, preventing and ultimately eliminating the disease.
Innovation in Cancer Care: Value, Costs and Quality
When considering whether high-cost treatments for cancer and other serious diseases are worth the price, value should be defined from the patient’s viewpoint.